(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.02% ¥ 2 487.50
Live Chart Being Loaded With Signals
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs...
Stats | |
---|---|
Объем за сегодня | 1.10M |
Средний объем | 1.65M |
Рыночная капитализация | 1 550.87B |
EPS | ¥0 ( 2024-02-08 ) |
Дата следующего отчета о доходах | ( ¥25.37 ) 2024-05-08 |
Last Dividend | ¥2.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 34.60 |
ATR14 | ¥1.939 (0.08%) |
Объем Корреляция
Sysmex Corporation Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Sysmex Corporation Корреляция - Валюта/Сырье
Sysmex Corporation Финансовые показатели
Annual | 2022 |
Выручка: | ¥410.50B |
Валовая прибыль: | ¥216.08B (52.64 %) |
EPS: | ¥72.94 |
FY | 2022 |
Выручка: | ¥410.50B |
Валовая прибыль: | ¥216.08B (52.64 %) |
EPS: | ¥72.94 |
FY | 2022 |
Выручка: | ¥363.78B |
Валовая прибыль: | ¥190.59B (52.39 %) |
EPS: | ¥210.88 |
FY | 2021 |
Выручка: | ¥305.07B |
Валовая прибыль: | ¥154.30B (50.58 %) |
EPS: | ¥158.65 |
Financial Reports:
No articles found.
Sysmex Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥2.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.500 | 2001-03-27 |
Last Dividend | ¥2.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥628.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.53 | |
Div. Directional Score | 9.65 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8154.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7513.T | Ex Dividend Junior | 2023-08-30 | Sporadic | 0 | 0.00% | |
6741.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6082.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4763.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
4004.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3202.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2208.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9069.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7956.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.103 | 1.500 | 7.94 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0794 | 1.200 | 7.35 | 8.82 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.87 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.390 | -1.000 | 6.10 | -6.10 | [0 - 1] |
currentRatioTTM | 3.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.972 | 0.800 | 3.11 | 2.49 | [0.8 - 2.5] |
cashRatioTTM | 0.603 | 1.500 | 7.76 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0882 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.92 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 108.38 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 28.58 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.123 | -1.500 | 9.51 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.168 | 1.000 | 8.65 | 8.65 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.355 | 1.000 | 3.58 | 3.58 | [0.2 - 2] |
assetTurnoverTTM | 0.773 | 0.800 | 8.18 | 6.55 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.55 | 1.000 | 6.61 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.92 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 28.58 | 2.00 | 0.474 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.25 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 108.38 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.390 | 1.500 | 6.10 | -6.10 | [0 - 1] |
pegRatioTTM | 0.907 | 1.500 | 7.28 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.155 | 1.000 | 8.63 | 0 | [0.1 - 0.5] |
Total Score | 6.53 |
Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа